All In Biotech

Drug Trial Radar · NCT02494778

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

248

Actual

Start

Sep 24, 2015

Primary completion

Jan 12, 2018

Study completion Jan 12, 2018

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
First posted
Jul 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

Conditions

  • Huntington's Disease

Interventions

  • PridopidineDrug

    45 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse EventsTime frame: 106 weeks

Locations

46 sites in 11 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 12204

    Los Angeles, California

  • Teva Investigational Site 12201

    Englewood, Colorado

  • Teva Investigational Site 12196

    Washington D.C., District of Columbia

  • Teva Investigational Site 12206

    Baltimore, Maryland

  • Teva Investigational Site 12200

    Manhasset, New York

  • Teva Investigational Site 12203

    New York, New York

  • Teva Investigational Site 12198

    Rochester, New York

  • Teva Investigational Site 12211

    Winston-Salem, North Carolina

  • Teva Investigational Site 12209

    Pittsburgh, Pennsylvania

  • Teva Investigational Site 12208

    Salt Lake City, Utah

  • Teva Investigational Site 12210

    Richmond, Virginia

  • Teva Investigational Site 78055

    Caulfield South, Australia

  • Teva Investigational Site 78058

    West Perth, Australia

  • Teva Investigational Site 78057

    Westmead, Australia

  • Teva Investigational Site 33021

    Innsbruck, Austria

  • Teva Investigational Site 33027

    Vienna, Austria

  • Teva Investigational Site 11036

    Toronto, Ontario, Canada

  • Teva Investigational Site 35123

    Angers, France

  • Teva Investigational Site 35122

    Créteil, France

  • Teva Investigational Site 35125

    Lille, France

  • Teva Investigational Site 35124

    Marseille, France

  • Teva Investigational Site 35121

    Salouël, France

  • Teva Investigational Site 35165

    Toulouse, France

  • Teva Investigational Site 32408

    Berlin, Germany

  • Teva Investigational Site 32410

    Bochum, Germany

  • Teva Investigational Site 32409

    Münster, Germany

  • Teva Investigational Site 32407

    Ulm, Germany

  • Teva Investigational Site 30083

    Florence, Italy

  • Teva Investigational Site 30080

    Milan, Italy

  • Teva Investigational Site 30082

    Naples, Italy

  • Teva Investigational Site 30081

    San Giovanni Rotondo, Italy

  • Teva Investigational Site 38059

    Leiden, Netherlands

  • Teva Investigational Site 53150

    Gdansk, Poland

  • Teva Investigational Site 53149

    Krakow, Poland

  • Teva Investigational Site 53148

    Poznan, Poland

  • Teva Investigational Site 53151

    Warsaw, Poland

  • Teva Investigational Site 50215

    Kazan', Russia

  • Teva Investigational Site 50213

    Moscow, Russia

  • Teva Investigational Site 50214

    Nyznij Novgorod, Russia

  • Teva Investigational Site 34058

    Birmingham, United Kingdom

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.